Advertisement
ARGX vs GMAB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and GMAB is a Hold.
ARGX's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for ARGX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 15 of the 20 cases the stock moved higher. This puts the odds of a move higher at 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 218 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
ARGX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARGX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for ARGX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. ARGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.088) is normal, around the industry mean (26.823). P/E Ratio (29.519) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (438.009).
Aroon Indicator for GMAB shows an upward move is likely
GMAB's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 211 similar instances where the Aroon Indicator showed a similar pattern. In 147 of the 211 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 15, 2026. You may want to consider a long position or call options on GMAB as a result. In 54 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
Following a +3.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 195 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for GMAB moved out of overbought territory on October 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 22 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 57 cases where GMAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for GMAB turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 30 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
GMAB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.819) is normal, around the industry mean (26.823). P/E Ratio (28.884) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARGX | GMAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 84 Overvalued | |
PROFIT vs RISK RATING 1..100 | 22 | 100 | |
SMR RATING 1..100 | 41 | 59 | |
PRICE GROWTH RATING 1..100 | 71 | 38 | |
P/E GROWTH RATING 1..100 | 36 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARGX's Valuation (83) in the Pharmaceuticals Other industry is in the same range as GMAB (84) in the null industry. This means that ARGX’s stock grew similarly to GMAB’s over the last 12 months.
ARGX's Profit vs Risk Rating (22) in the Pharmaceuticals Other industry is significantly better than the same rating for GMAB (100) in the null industry. This means that ARGX’s stock grew significantly faster than GMAB’s over the last 12 months.
ARGX's SMR Rating (41) in the Pharmaceuticals Other industry is in the same range as GMAB (59) in the null industry. This means that ARGX’s stock grew similarly to GMAB’s over the last 12 months.
GMAB's Price Growth Rating (38) in the null industry is somewhat better than the same rating for ARGX (71) in the Pharmaceuticals Other industry. This means that GMAB’s stock grew somewhat faster than ARGX’s over the last 12 months.
GMAB's P/E Growth Rating (8) in the null industry is in the same range as ARGX (36) in the Pharmaceuticals Other industry. This means that GMAB’s stock grew similarly to ARGX’s over the last 12 months.
| ARGX | GMAB | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 75% | 3 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 71% | 3 days ago 72% |
| Momentum ODDS (%) | N/A | 4 days ago 64% |
| MACD ODDS (%) | N/A | 3 days ago 68% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 71% |
| TrendMonth ODDS (%) | 3 days ago 62% | 3 days ago 64% |
| Advances ODDS (%) | 4 days ago 71% | 4 days ago 63% |
| Declines ODDS (%) | 6 days ago 63% | 11 days ago 71% |
| BollingerBands ODDS (%) | 3 days ago 73% | 3 days ago 59% |
| Aroon ODDS (%) | 3 days ago 55% | 3 days ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARGX’s FA Score shows that 1 FA rating(s) are green while GMAB’s FA Score has 1 green FA rating(s).
- ARGX’s FA Score: 1 green, 4 red.
- GMAB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARGX’s TA Score shows that 4 TA indicator(s) are bullish while GMAB’s TA Score has 3 bullish TA indicator(s).
- ARGX’s TA Score: 4 bullish, 4 bearish.
- GMAB’s TA Score: 3 bullish, 5 bearish.
Price Growth
ARGX (@Biotechnology) experienced а -0.71% price change this week, while GMAB (@Biotechnology) price change was -0.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
ARGX is expected to report earnings on Oct 22, 2026.
GMAB is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GMAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
|---|---|---|---|---|
| GMAB | 100% | -2.17% | ||
| AXON - GMAB | 47% Loosely correlated | -6.45% | ||
| PCVX - GMAB | 42% Loosely correlated | -2.53% | ||
| RYTM - GMAB | 40% Loosely correlated | -2.05% | ||
| BCYC - GMAB | 40% Loosely correlated | -3.89% | ||
| EXEL - GMAB | 39% Loosely correlated | -0.95% | ||
More | ||||